Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8399514 | BIOGEN INC | Treatment for multiple sclerosis |
Feb, 2028
(4 years from now) | |
US10994003 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(11 years from now) | |
US10391160 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(11 years from now) | |
US10555993 | BIOGEN INC | Dimethyl fumarate and vaccination regimens |
Mar, 2035
(11 years from now) | |
US11007167 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US11246850 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US10959972 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US11129806 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) | |
US11007166 | BIOGEN INC | Methods of treating multiple sclerosis |
Nov, 2035
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
M (M) | Feb 5, 2023 |
Drugs and Companies using DIMETHYL FUMARATE ingredient
Market Authorisation Date: 27 March, 2013
Treatment: Method of treating multiple sclerosis; Method of treating relapsing forms of multiple sclerosis before and after administering an inactive vaccine
Dosage: CAPSULE, DELAYED RELEASE;ORAL
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8669281 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
US10080733 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9090558 | BIOGEN INC | Prodrugs of fumarates and their use in treating various diseases |
Sep, 2033
(9 years from now) |
Drugs and Companies using DIROXIMEL FUMARATE ingredient
Market Authorisation Date: 29 October, 2019
Treatment: Method of treating multiple sclerosis
Dosage: CAPSULE, DELAYED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic